ＮａｐｓｉｎＡ和ＳＰ-Ａ在原发性肺腺癌及肺转移癌中的作用研究

目的　研究探讨ＮａｐｓｉｎＡ和表面活性蛋白Ａ（ＳＰ-Ａ）在原发性肺腺癌和肺转移癌组织中的表达及其临床意义。方法　收集上海长海医院２００７年至２００８年１０１例原发性肺腺癌和２７例肺转移癌组织标本，采集病例相关的临床病理资料。采用免疫组化ＥｎＶｉｓｉｏｎ两步法分别检测ＮａｐｓｉｎＡ和ＳＰ-Ａ的表达并对其结果进行分析。结果　ＮａｐｓｉｎＡ在原发性肺腺癌中阳性率为８５.１％，均为强阳性表达。ＳＰ-Ａ阳性率为５３.５％，表现为弱阳性到强阳性不等。单因素分析显示，ＮａｐｓｉｎＡ的表达与患者性别、吸烟史、有无淋巴结转移及腺癌分化程度密切相关（Ｐ＜０.０５）。多因素Ｌｏｇｉsｔｉｃ回归分析表明，患者的吸烟史（回归系数－１.８４１，Ｐ＝０.０２８）及腺癌的分化程度（回归系数－２.６５４，Ｐ＝０.００２）为ＮａｐｓｉｎＡ表达的影响因素，吸烟患者ＮａｐｓｉｎＡ表达少，腺癌分化越差表达也越少；而ＳＰ-Ａ表达与患者临床病理特征无显著联系（Ｐ＞０.０５）。在２７例转移性肺癌包括１９例肺转移性腺癌中，ＮａｐｓｉｎＡ和ＳＰ-Ａ均为阴性表达。结论　ＮａｐｓｉｎＡ对原发性肺腺癌有极高的特异性，有利于原发性肺腺癌和肺转移癌的鉴别，其在肺腺癌诊断中的应用价值优于ＳＰ-Ａ。

Expression and clinical significance of Napsin A and SP-A in primary lung adenocarcinoma and metastatic lung cancer

Objective To investigate the expression and clinical significance of Napsin A and SP-A(surfactant protein A,SP-A)in primary lung adenocarcinoma and metastatic lung cancer.Methods The expression of napsin A and SP-A were examined in 101 cases of primary lung adenocarcinoma and 27 cases of metastatic lung cancer by immunohistochemical En Vision two-step method,together with their clinicopathologic data.Results Napsin A was expressed in 85.1% of primary lung adenocarcinoma,which were all strong positive.Positi...